首页> 外文期刊>Journal of Translational Medicine >Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)
【24h】

Intra-articular injection of two different doses of autologous bone marrow mesenchymal stem cells versus hyaluronic acid in the treatment of knee osteoarthritis: long-term follow up of a multicenter randomized controlled clinical trial (phase I/II)

机译:关节内注射两种不同剂量的自体骨髓间充质干细胞与透明质酸治疗膝关节骨性关节炎:多中心随机对照临床试验的长期随访(I / II期)

获取原文
           

摘要

Mesenchymal stromal cells (MSCs) are a promising option to treat knee osteoarthritis (OA). Their safety and usefulness have been reported in several short-term clinical trials but less information is available on the long-term effects of MSC in patients with osteoarthritis. We have evaluated patients included in our previous randomized clinical trial (CMM-ART, NCT02123368) to determine their long-term clinical effect. A phase I/II multicenter randomized clinical trial with active control was conducted between 2012 and 2014. Thirty patients diagnosed with knee OA were randomly assigned to Control group, intraarticularly administered hyaluronic acid alone, or to two treatment groups, hyaluronic acid together with 10?×?106 or 100?×?106 cultured autologous bone marrow-derived MSCs (BM-MSCs), and followed up for 12?months. After a follow up of 4?years adverse effects and clinical evolution, assessed using VAS and WOMAC scorings are reported. No adverse effects were reported after BM-MSCs administration or during the follow-up. BM-MSCs-administered patients improved according to VAS, median value (IQR) for Control, Low-dose and High-dose groups changed from 5 (3, 7), 7 (5, 8) and 6 (4, 8) to 7 (6, 7), 2 (2, 5) and 3 (3, 4), respectively at the end of follow up (Low-dose vs Control group, p?=?0.01; High-dose vs Control group, p?=?0.004). Patients receiving BM-MSCs also improved clinically according to WOMAC. Control group showed an increase median value of 4 points (??11;10) while Low-dose and High-dose groups exhibited values of ??18 (??28;??9) and ??10 (??21;??3) points, respectively (Low-dose vs Control group p?=?0.043). No clinical differences between the BM-MSCs receiving groups were found. Single intraarticular injection of in vitro expanded autologous BM-MSCs is a safe and feasible procedure that results in long-term clinical and functional improvement of knee OA.
机译:间充质基质细胞(MSCs)是治疗膝骨关节炎(OA)的有前途的选择。在一些短期临床试验中已经报道了它们的安全性和实用性,但是关于MSC对骨关节炎患者长期作用的信息很少。我们已经评估了我们先前的随机临床试验(CMM-ART,NCT02123368)中包括的患者,以确定其长期临床疗效。在2012年至2014年之间进行了I / II期多中心,随机对照的临床试验,其中30例被诊断为膝关节炎的患者被随机分为对照组,分别关节内注射透明质酸或两个治疗组:透明质酸与10? ××106或100×××106培养的自体骨髓来源的MSC(BM-MSC),并随访12个月。随访了4年的不良反应和临床进展后,报告了使用VAS和WOMAC评分进行评估。 BM-MSCs给药后或随访期间未见不良反应。 BM-MSCs管理的患者根据VAS有所改善,对照组,低剂量和高剂量组的中位数(IQR)从5(3,7),7(5,8)和6(4,8)变为随访结束时分别为7(6,7),2(2,5)和3(3,4)(低剂量vs对照组,p <0.01);大剂量vs对照组,p ?=?0.004)。根据WOMAC,接受BM-MSC的患者在临床上也有所改善。对照组的中位值增加了4点(?? 11; 10),而低剂量和高剂量组的中位值增加了?? 18(?? 28; ?? 9)和?? 10(?? 21; 10)。 3点,分别为(低剂量vs对照组p≥0.043)。在BM-MSCs接受组之间没有发现临床差异。关节内单次注射体外扩增的自体BM-MSC是一种安全可行的方法,可长期改善膝OA的临床和功能。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号